eligibility_summary
Adults (≥18) with active, measurable relapsed/refractory multiple myeloma after ≥3 prior lines including an IMiD, proteasome inhibitor, and anti‑CD38, ECOG 0–2, adequate organs (Hgb ≥8, ANC >1000, Plt >50K, AST/ALT <3×ULN, CrCl ≥45), normal cardiac/pulmonary, no thromboembolism in 3 mo, no heparin allergy. Exclude: active uncontrolled infection, chronic immunosuppression (>40 mg/d prednisone eq), active CNS disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Descartes-15, an autologous mRNA-engineered CAR T-cell therapy (cellular gene therapy/immune cell therapy). Mechanism of action: Patient T cells are transiently modified to express a chimeric antigen receptor that binds BCMA (B-cell maturation antigen), CAR engagement activates T-cell effector functions, leading to targeted killing of myeloma cells. Study arms tested Descartes-15 with and without lymphodepletion. Targets: BCMA-expressing malignant plasma cells in relapsed/refractory multiple myeloma. Pathways/cells engaged: CAR-mediated T-cell activation and cytotoxicity directed at the BCMA axis on plasma cells. Status: Phase 1, terminated after enrollment completion.